Latuda lurasidone regulatory update

FDA accepted for review 2 sNDAs from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Latuda lurasidone to treat adult patients with depressive episodes associated with bipolar I disorder as a...